Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection
Line K. Vibholm(Aarhus University), Ole S. Søgaard(Aarhus University Hospital), Katrine Laura Rasmussen(Aarhus University Hospital), Wim Trypsteen(Ghent University Hospital), Jesper Falkesgaard Højen(Aarhus University), Judith Grau-Expósito(Vall d'Hebron Institut de Recerca), Mathias Lichterfeld(Ragon Institute of MGH, MIT and Harvard), Martin Tolstrup(Aarhus University), Sofie Rutsaert, Satish K. Pillai(University of California, San Francisco), Andreas Munk Petersen(University of Copenhagen), Mariane Høgsbjerg Schleimann(Aarhus University), Paul W. Denton(University of Nebraska at Omaha), Jørgen Agnholt(Aarhus University), María J. Buzón(Universitat Autònoma de Barcelona), Rikke Olesen(Aarhus University Hospital), Anders Dige(Aarhus University), Mohamed Abdel‐Mohsen(The Wistar Institute), Thomas Benfield(University of Copenhagen), Rasmus Offersen(Aarhus University), Lars Østergaard(Aarhus University), Xutao Deng(University of California, San Francisco), Linos Vandekerchove, Thomas A. Rasmussen(Aarhus University Hospital), Burghardt Wittig, Ward De Spiegelaere(Unknown)
Cited by 146
Related Papers
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
|PLoS Pathogens|2015|522
The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020
|Clinical Chemistry|2020|501
Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021
|Nature Medicine|2021|367